Webinar Video | Life Sciences Session #2: Vaccine liability: what if vaccination goes wrong?

Webinar Video | Life Sciences Session #2: Vaccine liability: what if vaccination goes wrong?
January 26, 2021

The ongoing vaccination campaign against Covid-19 raises the question of possible side effects and of the potential liability for damages arising from the use of vaccines used against this disease. Christophe Ronse and Lauranne Truyens highlight and discuss the various legal issues arising in such context, both from a regulatory and from a civil law viewpoint.

Contact

  • Christophe Ronse

    Partner

  • Lauranne Truyens

    Managing Associate

Recommended articles

January 08, 2026

Belgian Parliament has adopted urgent 2026 healthcare budget measures: what’s the impact on the pharma industry?

Over the Christmas break, the Belgian Parliament adopted an urgent law with several measures linked to the approved 2026 healthcare budget, with effect from 1 January 2026. The law is intentionally limited to provisions that must enter into force immediately to ensure that the required savings and revenues are available from the start of the […]

Read on
December 12, 2025

EU Reaches Pharma Package Deal: Key Changes at a Glance

On 11 December 2025, following overnight negotiations, the Council and the European Parliament announced a political agreement on the long-awaited Pharma Package (see here). The reform seeks to update the EU’s pharmaceutical rulebook to facilitate access to safe and affordable treatments and bolster the life sciences sector’s competitiveness. While more detailed information is still trickling […]

Read on
November 07, 2025

Belgian Constitutional Court strikes down pharma industry ‘unavailability contribution’

The Belgian Constitutional Court (“CC”), on 6 November 2025, annulled some provisions of the Law of 18 May 2024 containing various provisions on health and finance, striking down the pharma industry ‘unavailability contribution’. Background Parts of the above Law sought to protect patients from bearing additional costs when reimbursable medicines become unavailable and must be […]

Read on